Your browser is no longer supported. Please, upgrade your browser.
Settings
NK [NASD]
NantKwest, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own3.70% Shs Outstand108.25M Perf Week27.89%
Market Cap2.05B Forward P/E- EPS next Y-0.84 Insider Trans-11.41% Shs Float34.79M Perf Month71.88%
Income-75.90M PEG- EPS next Q-0.18 Inst Own9.90% Short Float17.86% Perf Quarter98.92%
Sales0.10M P/S20746.43 EPS this Y42.60% Inst Trans3.84% Short Ratio2.92 Perf Half Y19.40%
Book/sh1.37 P/B13.39 EPS next Y-9.10% ROA-46.90% Target Price18.00 Perf Year149.52%
Cash/sh0.80 P/C23.05 EPS next 5Y-1.70% ROE-56.10% 52W Range2.52 - 20.05 Perf YTD37.58%
Dividend- P/FCF- EPS past 5Y-54.10% ROI- 52W High-8.53% Beta2.44
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low627.78% ATR2.02
Employees160 Current Ratio4.70 Sales Q/Q466.70% Oper. Margin- RSI (14)66.59 Volatility12.47% 14.82%
OptionableYes Debt/Eq0.02 EPS Q/Q-27.00% Profit Margin- Rel Volume0.73 Prev Close17.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.13M Price18.34
Recom2.00 SMA2025.75% SMA5062.18% SMA200109.04% Volume1,561,404 Change6.32%
Jul-08-20Initiated Piper Sandler Overweight $18
May-31-19Downgrade Citigroup Neutral → Sell
Nov-30-18Upgrade Citigroup Sell → Neutral
Oct-17-18Downgrade Citigroup Neutral → Sell
Aug-09-18Upgrade Citigroup Sell → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Mar-17-17Reiterated FBR & Co. Outperform $22 → $9
Jan-24-17Downgrade Jefferies Buy → Hold
Jun-02-16Initiated Raymond James Mkt Perform
Apr-04-16Reiterated Canaccord Genuity Buy $20 → $18
Mar-31-16Reiterated FBR Capital Outperform $30 → $29
Dec-22-15Initiated Canaccord Genuity Buy $20
Oct-28-15Initiated FBR Capital Outperform $30
Aug-24-15Initiated Piper Jaffray Overweight $38
Aug-24-15Initiated MLV & Co Buy $35
Aug-24-15Initiated Jefferies Buy $33
Aug-24-15Initiated Citigroup Buy $45
Jan-19-21 08:01AM  
Jan-18-21 12:00AM  
Jan-15-21 09:00PM  
Jan-14-21 04:43PM  
07:56AM  
06:44AM  
Jan-13-21 09:00PM  
06:01PM  
02:20AM  
Jan-12-21 07:11PM  
Jan-07-21 04:18PM  
Jan-06-21 09:00AM  
Jan-05-21 11:18PM  
05:36PM  
Jan-02-21 07:30AM  
Dec-30-20 09:00PM  
10:10AM  
08:49AM  
07:18AM  
Dec-29-20 08:58PM  
06:40PM  
Dec-28-20 08:20PM  
11:22AM  
08:07AM  
Dec-24-20 10:08AM  
Dec-23-20 09:00PM  
05:58PM  
Dec-22-20 10:02AM  
09:48AM  
Dec-21-20 07:56PM  
06:47PM  
12:49PM  
10:10AM  
06:05AM  
06:05AM  
Dec-10-20 11:18PM  
09:48PM  
Dec-09-20 05:13AM  
Dec-07-20 12:00PM  
Nov-23-20 09:00AM  
Nov-18-20 09:15AM  
Nov-10-20 07:00AM  
Nov-09-20 03:07PM  
09:00AM  
Oct-26-20 04:15PM  
Oct-21-20 05:06PM  
Oct-15-20 06:00AM  
Oct-06-20 04:05PM  
Oct-05-20 12:42PM  
Sep-21-20 09:00AM  
Sep-10-20 09:00AM  
Aug-24-20 09:00AM  
Aug-19-20 10:36AM  
Aug-10-20 07:00AM  
Jul-28-20 12:33PM  
Jul-06-20 10:48AM  
Jul-02-20 10:24AM  
Jun-29-20 04:05PM  
02:06PM  
Jun-25-20 01:01AM  
Jun-24-20 04:15PM  
Jun-10-20 09:00AM  
May-31-20 09:13PM  
May-27-20 01:56PM  
12:00PM  
May-26-20 09:30AM  
May-19-20 08:00AM  
May-18-20 08:30AM  
May-15-20 07:49AM  
May-14-20 04:25PM  
Apr-29-20 04:15PM  
Apr-14-20 04:55PM  
10:55AM  
08:30AM  
Mar-19-20 08:00AM  
Jan-17-20 08:42AM  
Jan-16-20 08:00AM  
Jan-14-20 08:00AM  
Jan-13-20 05:22PM  
Jan-06-20 11:50AM  
Dec-20-19 02:55PM  
Dec-16-19 07:00AM  
Dec-03-19 07:59AM  
Dec-02-19 04:05PM  
Nov-27-19 08:00AM  
Nov-07-19 04:15PM  
01:14PM  
Oct-02-19 10:40AM  
Aug-27-19 10:21AM  
Jul-11-19 06:58AM  
Jun-24-19 08:00AM  
Jun-06-19 04:10PM  
Jun-04-19 08:00AM  
07:45AM  
Jun-03-19 02:50PM  
08:00AM  
May-31-19 08:00AM  
May-23-19 10:13AM  
May-01-19 08:00AM  
Apr-01-19 08:00AM  
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nelson SonjaChief Financial OfficerJan 12Option Exercise3.0711,36434,88731,774Jan 13 04:19 PM
Nelson SonjaChief Financial OfficerJan 12Sale15.0016,364245,46015,410Jan 13 04:19 PM
Nelson SonjaChief Financial OfficerJan 04Option Exercise3.0722,72969,77859,681Jan 06 08:25 PM
Nelson SonjaChief Financial OfficerJan 04Sale13.6239,271534,93820,410Jan 06 08:25 PM
Simon Barry J.See remarksDec 22Option Exercise2.00130,000259,7923,300,540Dec 28 06:23 PM
Simon Barry J.See remarksDec 22Sale18.05130,0002,346,6043,170,540Dec 28 06:23 PM
Thomas John CDirectorDec 10Sale10.8342,592461,122207,477Dec 11 04:20 PM
Thomas John CDirectorAug 19Sale9.1920,000183,800250,069Aug 21 04:38 PM
Thomas John CDirectorAug 13Sale9.4240,000376,600270,069Aug 13 07:13 PM
Thomas John CDirectorAug 11Sale10.3520,000207,042310,069Aug 13 07:13 PM
Cohen CherylDirectorAug 11Sale9.9630,000298,785270,925Aug 13 07:10 PM
DRISCOLL FREDERICK WDirectorAug 11Sale10.2365,300668,052109,235Aug 13 04:31 PM
Nelson SonjaChief Financial OfficerAug 02Option Exercise0.0010,000040,410Aug 04 09:05 PM
Simon Barry J.See remarksJul 21Option Exercise2.001,5653,1273,172,105Jul 22 04:05 PM
Simon Barry J.See remarksJul 21Sale15.501,56524,2583,170,540Jul 22 04:05 PM
Simon Barry J.See remarksJul 20Option Exercise1.92128,435246,7673,298,975Jul 22 04:05 PM
Simon Barry J.See remarksJul 20Sale15.53128,4351,995,0713,170,540Jul 22 04:05 PM
Simon Barry J.See remarksJul 08Option Exercise1.7639,95070,1283,210,490Jul 10 05:00 PM
Simon Barry J.See remarksJul 08Sale13.1439,950524,7593,170,540Jul 10 05:00 PM
Simon Barry J.See remarksJun 30Option Exercise1.769163,170,549Jul 02 06:32 PM
Simon Barry J.See remarksJun 30Sale13.0091173,170,540Jul 02 06:32 PM
SOON-SHIONG PATRICKChairman and CEOJun 29Buy12.123,710,00044,965,20023,750,750Jun 29 07:36 PM
Simon Barry J.See remarksJun 23Option Exercise1.7629,60951,9763,200,149Jun 23 09:45 PM
Simon Barry J.See remarksJun 23Sale13.0129,609385,1333,170,540Jun 23 09:45 PM
Simon Barry J.See remarksJun 22Option Exercise1.76136,729240,0143,327,235Jun 23 09:45 PM
Simon Barry J.See remarksJun 22Sale10.24156,6951,604,1803,170,540Jun 23 09:45 PM
Simon Barry J.See remarksJun 19Option Exercise1.769,33716,3903,204,243Jun 23 09:45 PM
Simon Barry J.See remarksJun 19Sale9.0013,737123,6373,190,506Jun 23 09:45 PM
Simon Barry J.See remarksMay 27Sale7.5675,000567,3383,194,906May 29 04:27 PM
Simon Barry J.See remarksMay 21Sale5.5236,932203,6983,269,906May 22 05:37 PM
Simon Barry J.See remarksMay 11Sale5.5028,068154,5093,306,838May 13 08:04 PM
Nelson SonjaChief Financial OfficerMar 23Option Exercise0.0015,000036,542Mar 24 05:47 PM